We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





COVID-19 Antibody Test Results May Vary Based on Gender, New Study Suggests

By LabMedica International staff writers
Posted on 20 Apr 2021
A study suggests that clinical laboratories should anticipate gender-dependent differences in COVID-19 antibody levels as the findings showed these levels are significantly higher in males and that antibodies may last for four times longer in males.

The study by researchers at Cardiff Metropolitan University (Cardiff, UK) aimed to determine the antibody prevalence in a professional Welsh cohort and begin to explore the longevity of COVID-19 antibodies. More...
739 University staff members took part in the observational study to determine the prevalence of COVID-19 antibodies in a two-phase, single cohort study. All the participants were tested for IgM and IgG antibodies against COVID-19 using a lateral flow detection assay. Venous blood samples from positive participants and a randomly selected negative population were collected to confirm antibody titre, using two gold standard immunoassays.

The researchers found that 3.65% of the population tested positive for anti-bodies against COVID-19, with a higher prevalence seen in male participants (5% vs. 2.73% of females). In addition to gender, both pre-existing asthma and age were key determinants in antibody positivity. 78.26% retained antibodies at the three months follow up test. 36.36% of females lost antibody positivity between the three and six months time points compared with 8.3% of males. Lateral flow antibody testing was shown to have 96% sensitivity and 95% specificity compared with standard tests.

The researchers concluded that the prevalence of COVID-19 antibodies is evident in the asymptomatic population, and in 78.26% of those initially antibody positive prevails at approximately six months from perceived time of exposure. Additionally, males are four times more likely to retain antibodies for longer than females, making it important for clinical laboratories to recognize that COVID-19 test results may vary based on gender.

Related Links:
Cardiff Metropolitan University


Platinum Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.